Cocarnitin B12 500 mg + 2 mg 10 vials powder + solvent for oral suspension

Cocarnitin B12 500 mg + 2 mg 10 bottles powder + solvent for oral suspension is a drug specifically formulated to support energy metabolism and general well-being in situations of vitamin deficiency, nutritional deficits and states of debilitation. Each pack contains 10 bottles with powder and solvent, to be mixed to obtain an oral suspension that can be easily administered both to children that ad adults. The product combines two fundamental active ingredients: L-carnitine (500 mg per vial), known for its role in the transport of fatty acids into mitochondria and energy production, and cobamamide (2 mg per cap), an active form of vitamin B12 essential for the synthesis of red blood cells and the correct functioning of the nervous system.

Thanks to its composition, Cocarnitin B12 turns out to be a restorative ed energizing ideal in case of lack of appetite, weight loss pathological, growth delays in children, states of convalescence e asthenia. It is particularly suitable for the treatment of states of malnutrition in infants, premature babies and children, but it is also used in internal medicine for adults who present thinness without apparent cause, hypoproteinemias from liver disease or nephrosis, or who require a anticatabolic during prolonged cortisone therapy or thyrotoxicosis.

The wording in vials with powder and solvent guarantees maximum stability of the active ingredients and simple and safe preparation of the oral suspension. The selected excipients, including sorbitol, sucrose and natural flavourings, make the product pleasant to the taste and suitable even for the little ones. Cocarnitin B12 it is the optimal solution for those looking for a supplement effective for stimulating the metabolism, promoting growth and energy recovery, and counteracting the symptoms related to vitamin deficiencies e debilitation physics.

INDICATIONS

Why is Cocarnitin B12 500 mg + 2 mg 10 bottles powder + solvent for oral suspension used? What is it for?

Paediatrics: All states of malnutrition in children, infants and premature babies, growth delays, weight insufficiency, dystrophies, anorexia, weight loss from any cause, states of post-infectious debilitation. Internal medicine: Pathological weight loss of any etiology, thinness without apparent cause, loss of appetite, asthenia, convalescence, as an anti-catabolic in prolonged cortisone therapies and in thyrotoxicosis, in hypoproteinemias of liver disease and nephrosis.

ACTIVE INGREDIENTS AND EXCIPIENTS

What is the composition of Cocarnitin B12 500 mg + 2 mg 10 bottles powder + solvent for oral suspension?

Composition

One cap contains: Active ingredient: Cobamamide 2 mg. One vial contains: Active ingredient: L-Carnitine internal salt 500 mg. Excipients with known effects: sorbitol solution 70% (E420). 4.075 g, sucrose 1.5 g, sodium benzoate 0.048 (E211) g.

Excipients

The cap contains: polyethylene glycol 4000, mannitol powder. The vial contains: sorbitol solution 70%, sodium benzoate, black cherry juice, orgeat juice, sucrose, demineralised water to taste.

DOSAGE

How is Cocarnitin B12 500 mg + 2 mg 10 bottles powder + solvent for oral suspension taken?

Infants and premature babies: one vial a day diluted in water. Children and adolescents: 1-2 vials per day diluted in water. Adults: 2-3 vials per day. Special populations. Elderly patients: No dosage adjustments of CoCarnitin B12 are necessary in elderly patients. Patients with renal insufficiency: Patients with severe impairment of renal function should not be treated with the administration of high doses of L-Carnitine for prolonged periods orally because it can induce an accumulation of potentially toxic metabolites (see the section "What are the warnings of Cocarnitin B12 500 mg + 2 mg 10 bottles powder + solvent for oral suspension?"). No data are available for the use of Vitamin B12 in patients with renal insufficiency. Patients with hepatic impairment: No data are available in patients with hepatic impairment. The characteristics of CoCarnitin B12 may be altered by exposure to light and if it is not used immediately after mixing with liquids or food.

CONTRAINDICATIONS AND SIDE EFFECTS

When should Cocarnitin B12 500 mg + 2 mg 10 bottles powder + solvent for oral suspension not be used and what side effects can it cause?

Contraindications

Hypersensitivity to the active substance or to any of the excipients (see the section "What is the composition of Cocarnitin B12 500 mg + 2 mg 10 bottles powder + solvent for oral suspension?").

Side effects

Adverse reactions from all sources (clinical studies, published clinical data for individual active substances and post-marketing data for CoCarnitin B12) are listed below by MedDRA system organ class. Within each class, adverse reactions are classified according to frequency. Within each frequency grouping, adverse reactions are classified in order of decreasing seriousness. Furthermore, the corresponding frequency category for each adverse reaction is based on the following convention (CIOMS III): very common (≥1/10), common (≥1/100, less than 1/10), uncommon (≥1/1,000, less than 1/100), rare (≥1/10,000, less than 1/1,000) very rare (less than 1/10,000), not known (frequency cannot be estimated from the available data). Pathologies of the nervous system. Uncommon: Headache. Gastrointestinal disorders. Uncommon: Abdominal distension, Gastrointestinal pain, Vomiting; Common: Abdominal pain, Diarrhoea, Nausea. Cases of seizures have been reported in patients, with or without a history of seizure activity, who had received L-Carnitine orally or intravenously ((see section "What are the warnings of Cocarnitin B12 500 mg + 2 mg 10 bottles powder + solvent for oral suspension?")). Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse.

INTERACTIONS

Which medicines or foods can modify the effect of Cocarnitin B12 500 mg + 2 mg 10 bottles powder + solvent for oral suspension?

Oral anticoagulants: Very rare cases of increased INR (International Normalized Ratio) have been reported in patients undergoing concomitant therapy with L-Carnitine and coumarin drugs ((see the section "What are the warnings of Cocarnitin B12 500 mg + 2 mg 10 bottles powder + solvent for oral suspension?")). The INR or other appropriate coagulation tests should be checked weekly until the values ​​stabilize and then monthly, in patients taking L-Carnitine together with coumarin drugs ((see the section "What are the warnings of Cocarnitin B12 500 mg + 2 mg 10 bottles powder + solvent for oral suspension?")). Other interactions: Concomitant administration of L-Carnitine with drugs that induce hypocarnitinemia due to increased renal carnitine loss (valproic acid, prodrugs containing pivalic acid, cephalosporins, cisplatin, carboplatin and ifosfamide) may reduce the availability of L-Carnitine. There are no known interactions of Vitamin B12 with other drugs.

PREGNANCY AND BREASTFEEDING

Can Cocarnitin B12 500 mg + 2 mg 10 bottles powder + solvent for oral suspension be used during pregnancy and breastfeeding?

Pregnancy: L-Carnitine crosses the placenta. Carnitine levels in newborns reflect those of the mother. There are no clinical studies available with the administration of vitamin B12 or CoCarnitin B12 in pregnant women. Breastfeeding: L-Carnitine is the normal component present in breast milk. There are no clinical studies available in breastfeeding women with supplements containing L-Carnitine or CoCarnitin B12. Fertility: Clinical fertility studies with L-Carnitine have reported no safety concerns. There are no clinical studies on fertility with vitamin B12.

WARNINGS

What are the warnings of Cocarnitin B12 500 mg + 2 mg 10 bottles powder + solvent for oral suspension?

Warnings and precautions

Chronic oral administration of high doses of L-Carnitine in patients with severe renal insufficiency can induce an accumulation of potentially toxic metabolites: trimethylamine (TMA) and trimethylamine-N oxide (TMAO). Very rare cases of increased INR (International Normalized Ratio) have been reported in patients undergoing concomitant therapy with L-Carnitine and coumarin drugs. The INR or other appropriate coagulation tests - must be checked weekly until the values ​​stabilize and subsequently monthly in patients taking anticoagulants together with L-Carnitine. Cases of seizures have been reported in patients, with or without a history of seizure activity, who have received L-Carnitine orally or intravenously. In patients with underlying predisposing conditions, treatment with L-Carnitine may trigger seizures. CoCarnitin B12 contains 4.075 g of sorbitol per vial. Sorbitol can cause gastrointestinal upset and have a mild laxative effect. The additive effect of co-administration of medicinal products containing sorbitol (or fructose) and daily dietary intake of sorbitol (or fructose) should be considered. The sorbitol content in oral medicinal products may modify the bioavailability of other co-administered oral medicinal products. Patients with hereditary fructose intolerance should not be given this medicine. CoCarnitin B12 contains 1.5 g of sucrose per vial. Sucrose can be harmful to your teeth. Patients suffering from rare problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. CoCarnitin B12 contains 0.048 g sodium benzoate per vial. The increase in bilirubin following its detachment from albumin can increase neonatal jaundice which can progress to kernicterus (deposits of unconjugated bilirubin in the brain tissue). This medicinal product contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'. Given the particular lability and photosensitivity of Cobamamide, any solution of the product in liquids or its mixing in other foods must take place immediately before the moment of administration. The drug is not habit-forming or addictive. Products containing Cobamamide should not be administered to anemic subjects unless on the basis of investigations aimed at establishing the exact nature of the anemia.

Overdose

No cases of overdose have been reported.

Driving vehicles and using machinery

CoCarnitin B12 does not affect the ability to drive or use machines.

CONSERVATION

How is Cocarnitin B12 500 mg + 2 mg 10 bottles powder + solvent for oral suspension stored?

Do not store above 25°C.

FORMAT

What is the format of Cocarnitin B12 500 mg + 2 mg 10 bottles powder + solvent for oral suspension?

DRUG LEGAL TEXT

Content responsibility

This sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.

Please note

The product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.

Data source: Farmadati Italia

Website: www.farmadati.it

The Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.

The Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO/IEC 27001:2017 for information security management systems.